deficiency, as VWF prevents FVIII from proteolysis. 3 Generally, patients with VWD are treated with desmopressin (DDAVP) or VWFcontaining concentrates when acute bleeding or trauma occurs, or to prevent bleeding in the surgical setting. The aim of treatment is to correct the VWF deficiency, and also to correct a FVIII deficiency, if this is present. In patients who do not respond adequately to DDAVP or have contra-indications for its use, treatment usually consists of combined VWF/FVIII factor concentrates amongst which the ratios of VWF activity (VWF:Act) over FVIII may differ. 4 Although clinical symptoms are generally milder than in haemophilia, dosing of perioperative treatment in VWD is more challenging due to variation in VWD types and mutations, 2,5 interpatient variability of residual endothelial VWF production, VWF secretion and clearance, as well as heterogeneity in types of factor concentrates with different ratios of VWF:Act/FVIII and VWF:Act/VWF antigen (VWF:Ag). 6, 7 Previous studies have, however, reported that surgical procedures can be performed safely in patients with VWD and that treatment with VWF-containing concentrates is efficacious. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In many countries, specific target levels are defined in national guidelines to safeguard haemostasis during surgery. These target values are based on expert opinion and limited observational research ( Figure 1 ). 18 Currently, calculation of the required doses of VWF and/or FVIII is based on body weight. In the Netherlands, dosing is FVIII level-based, due to the fact that FVIII is considered crucial in preventing surgical bleeding by its role in thrombin generation and consolidation of the fibrin plug. 17 However, momentarily VWF levels are increasingly monitored as rapid availability of VWF activity assay results is becoming mainstream. This may facilitate a more VWF-based dosing regimen in the near future. 19 Furthermore, it is increasingly common to label factor concentrates according to both FVIII and VWF content.
VWF/FVIII concentrates can be classified into three different groups according to VWF:Act/FVIII and VWF:Act/VWF:Ag ratios 7 Firstly, products with a VWF:Act/FVIII ratio of approximately 1 (with low or high VWF:Act/VWF:Ag ratio). Secondly, with a VWF:Act/FVIII ratio of >1 (with high VWF:Act/VWF:Ag ratio) and lastly, VWF concentrates with a VWF:Act/FVIII ratio of >10 (with also high VWF:Act/VWF:Ag ratio). In case the last concentrates are used perioperatively, patients with low circulating FVIII levels should receive this concentrate intravenously 6-8 hours before surgery, to allow endogenous FVIII to rise to haemostatically adequate levels.
Therefore, in emergency situations, a priming dose of FVIII in addition to VWF concentrate is often required. 20 Because FVIII production and secretion are normal in patients with VWD, infusion of exogenous VWF, which stabilizes and increases endogenous FVIII levels, together with exogenous FVIII, may lead to very high levels of FVIII (>2.70 IU/mL). 21 This is, of course, a possible risk factor for thrombosis. 22 It has been demonstrated that repetitive dosing of concentrates with a VWF:Act/FVIII ratio >1 will result in less accumulation of FVIII than concentrates with a ratio of approximately Choice of perioperative treatment is dependent on type and severity of VWD, while dosing of replacement therapy is dependent on type and extent of the surgical procedure. 18 In addition, treatment may differ due to interindividual differences in pharmacokinetic (PK) parameters such as clearance and half-life of both exogenous and endogenous VWF and FVIII. Studies report that perioperative VWF/FVIII concentrate consumption indeed varies substantially, from 27 to 146 VWF:Act IU/kg/day 8, 17 . As achieved VWF and FVIII levels have rarely been evaluated and reported in relation to efficacy, 24 we aimed to evaluate current perioperative management with VWF/FVIII concentrate in patients with VWD in relation to target levels as stated in national guidelines. This was done by assessing the extent to which predefined VWF:Act and FVIII target levels were actually achieved as well as by analysis of predictors of higher or lower VWF:Act and FVIII levels than targeted. Insight in these factors will help realize more efficacious and individualized treatment in VWD. In addition, collection of these data will help construct population PK models for patients with VWD in the near future.
| MATERIAL S AND ME THODS
This multicentre retrospective observational cohort study was 
| Subject selection

| Study objective
The study objective was to evaluate current perioperative management with a specific VWF/FVIII factor concentrate (Haemate ® P) in patients with VWD by specification of concentrate administration and analysis of subsequently achieved peak and trough levels of VWF:Act and FVIII in comparison with target VWF and FVIII levels as prescribed by national guidelines (Figure 1 ). 18 In this study, both potential predictors of low and high levels of VWF:Act and FVIII as well as variables associated with VWF/FVIII concentrate consumption were collected and evaluated. is adjusted according to VWF:Act and FVIII target levels specified in guidelines and depicted in Figure 1 . 18 In general, patients are treated 7-10 days in case of a major surgical procedure and 4-7 days in case of a minor surgical procedure. This is in accordance with the UKHCDO and Nordic guidelines. 27, 28 Perioperative dosing was left to discretion of treating physician. When patients were prescribed thromboprophylaxis, in the majority of patients low molecular weight heparin was used. Thromboprophylaxis was given at the discretion of the treating physician, taking type of surgery, duration of hospitalization and patient risk factors for thrombosis, such as age, body mass index, history of thrombosis and genetic predisposition for thrombosis into account.
| Laboratory assessment
| Data collection
Perioperative management with VWF/FVIII concentrate after first peak values was evaluated by comparing achieved VWF:Act and FVIII trough and steady-state levels to target VWF:Act and FVIII levels. Trough levels were defined as measurements prior to bolus infusion or measurements at least 12 hours after infusion, when no subsequent factor concentrate infusion was given. Redundantly, no peak levels after bolus infusion were included in these analyses.
Steady-state samples were defined as VWF and FVIII levels sampled when concentrate substitution is expected to equal elimination of VWF/FVIII concentrate when administered by continuous infusion.
In general, it is assumed that steady state will be reached after a loading dose has been administered and continuous infusion has started. 
| Statistical analysis
Descriptive data are presented as numbers with percentages for categorical variables and as medians with an interquartile range (IQR)
for continuous variables, as data were not normally distributed. The non-parametric Mann-Whitney U test was used to compare VWF/ FVIII concentrate consumption between surgical procedures of different severity. If a patient was subjected to two or more surgeries, calculations were only performed for the first surgical procedure. in the study population underwent multiple surgical procedures (Table 1) . Procedures were mainly orthopaedic (n = 36; 24%), general (n = 26; 18%) and gynaecological (n = 24; 16%). No differences in number and type of surgical procedures between VWD types were observed. Almost all patients received replacement therapy by bolus infusion (90%). Median duration of hospitalization was 6 days (Table 1) . Eleven (29%) and 52 (47%) patients with respectively a minor and major surgical procedure received thromboprophylaxis with low molecular weight heparin. In 51 surgical procedures, patients received tranexamic acid.
| RE SULTS
| Actual VWF:Act and FVIII levels compared to predefined target levels
No differences were observed in achieved VWF:Act and FVIII levels between patients with type 1, type 2 and type 3 VWD (14) 12 ( 
| Bleeding complications
Overall, occurrence of bleeding complications was not associated with a low trough VWF:Act and/or low FVIII (P = .95 and 0.25 respectively). Exception was one patient, undergoing a craniotomy with excessive blood loss with need for blood cell transfusions and presenting with lower trough VWF:Act (0.40 IU/mL) and FVIII (0.60 IU/ mL) levels (Table 2) . Clinically relevant bleeding only occurred in 5 (3.4%) surgical procedures, as four surgical procedures required red blood cell transfusion post surgery and only one a second surgical intervention ( Table 2) . Despite excessive FVIII levels, no thrombotic complications were reported. Of the 18 patients reaching very high (>2.70 IU/mL) FVIII levels, 61% received thromboprophylaxis with low molecular weight heparin.
| Treatment
Two patients with type 1 VWD received only desmopressin prior to surgery to achieve VWF:Act and FVIII target levels. After surgery, 
| Predictors of low and high VWF:Act and FVIII levels
It was only possible to evaluate predictors in patients with type 1 and 
| D ISCUSS I ON
This study is the largest so far evaluating perioperative management of patients with VWD in a resource-rich country. We present data that underline the complexity of VWF/FVIII concentrate dosing in this patient population, as illustrated by the fact that in patients with type 1 VWD, 65% of trough and steady-state VWF:Act and 91% of FVIII levels were ≥0.20 IU/mL above predefined target levels. In type 2 and type 3 VWD, respectively, 53% and 57% of VWF:Act and 72% and 73% of FVIII were ≥0.20 IU/mL above predefined target levels. In contrast to results in perioperative severe and moderate haemophilia A patients, 29 only a small percentage of patients with VWD experienced low levels in the first 36 hours after surgery, as only 16% of VWF:Act levels in patients with type 1 VWD and 38% and 29% of VWF:Act levels in patients with type 2 and 3 VWD, respectively, and only 8%, 14% and 11% of FVIII levels in, respectively, type 1, type 2 and type 3 VWD were below prescribed target level. This is probably due to FVIII-based dosing performed according to the Dutch national guidelines applied in this study. Although both VWF:Act and FVIII were measured perioperatively, VWF:Act was not directly available in most cases and could not be used to monitor perioperative VWF/FVIII concentrate management. In our cohort, prevalence of clinically relevant bleeding complications was low (3.4%) and not associated with achieved VWF:Act and/or FVIII. This is supported by oth- Although we observed high FVIII levels that confer a possible risk for thrombosis, 22, 32, 33 no thrombo-embolic complications were observed. Previously, Wells et al. demonstrated that FVIII levels above 2.70 IU/mL are associated with a higher risk of thrombosis in nonsurgical patients. 21 In our study, 8% of trough levels of FVIII were above 2.70 IU mL. Also, observed postoperative VWF:Act and FVIII levels were increased for only a brief period of time and coincide with physiological levels in healthy individuals without a bleeding disorder. 31 Mannucci et al. also reported this scarcity of thrombosis in perioperative VWD patients on replacement therapy. 32 In our study, it must also be taken into account that almost half of patients undergoing a major surgical procedure received thromboprophylaxis with low molecular weight heparin.
As reported, plasma-derived VWF/FVIII concentrate in this study (Haemate P ® ), has a VWF:Act/FVIII ratio of 2.4:1 and contains large amounts of high molecular-weight multimers, which are thought to be the most haemostatically potent multimers. 
| CON CLUS ION
Although perioperative replacement therapy in patients with VWD is successful with few bleeding complications, it can be optimized as patients are currently overtreated with accumulation of FVIII as a consequence, fortunately without thrombotic complications. Due to the complexity of treatment in VWD, we hypothesize that population PK models, which incorporate known and unknown modifying factors of clearance and other PK parameters of VWF/FVIII concentrates, may be promising tools for personalization of replacement therapy in all patients with VWD.
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